Knowledge and Attitudes Regarding Respiratory Syncytial Virus (RSV) Prevention: A Systematic Review.

Teresa Gavaruzzi, Andrea Ceccarelli, Camilla Nanni, Carloalberto Vignali, Valentina Colonnello, Marta Caserotti, Matteo Riccò, Davide Gori
Author Information
  1. Teresa Gavaruzzi: Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy. ORCID
  2. Andrea Ceccarelli: Department of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy.
  3. Camilla Nanni: Romagna Local Health Authority, 47121 Forlì, Italy.
  4. Carloalberto Vignali: Department of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy.
  5. Valentina Colonnello: Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy.
  6. Marta Caserotti: Department of Developmental Psychology and Socialization, University of Padova, 35131 Padova, Italy. ORCID
  7. Matteo Riccò: AUSL-IRCCS di Reggio Emilia, Servizio di Prevenzione e Sicurezza Negli Ambienti di Lavoro (SPSAL), Local Health Unit of Reggio Emilia, 42123 Reggio Emilia, Italy. ORCID
  8. Davide Gori: Department of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy. ORCID

Abstract

: New strategies for respiratory syncytial virus (RSV) prevention are available and are in development, but their acceptance is crucial to their effectiveness. Objectives: This systematic review aims to summarize current quantitative and qualitative evidence regarding knowledge and attitudes relating to RSV prevention. : Six databases (PubMed, Scopus, APA PsycArticles; APA PsycInfo; CINAHL Complete; Psychology and Behavioral Sciences Collection) and two preprint repositories (medRxiv and Preprints) were searched up until 23 December 2024 (PROSPERO: CRD42024602351). : Sixty-one articles were included, focusing on vaccination for the elderly and adults at risk (n = 10) or pregnant people (n = 24, of which 8 also examined preferences for maternal vs. infant immunization) and infant immunization (n = 27, of which 16 focused on palivizumab, with 6 focusing on adherence to its monthly administration). Eighteen articles assessed attitudes in healthcare professionals. Overall, findings showed limited knowledge and awareness of RSV but generally positive attitudes towards prevention strategies and moderate to high intentions and uptake rates. Protection against the disease and perceived severity promoted acceptance, whereas concerns about side effects hindered it. Maternal vaccination was more acceptable than infant immunization. : Attitudes towards RSV prevention options were generally favorable. Should more options become available, preferences may depend on which options are available, their characteristics, and how they are framed and presented. These insights highlight the importance of education on RSV grounded in decision-making literature, while recognizing the likely favorable reception of preventive measures across target age-populations.

Keywords

References

  1. Ambul Pediatr. 2002 Nov-Dec;2(6):444-8 [PMID: 12437390]
  2. Hum Vaccin Immunother. 2024 Dec 31;20(1):2303796 [PMID: 38297921]
  3. Clin Microbiol Infect. 2017 Apr;23(4):253-259 [PMID: 27903461]
  4. Pediatr Infect Dis J. 2019 Sep;38(9):944-951 [PMID: 31261362]
  5. Healthcare (Basel). 2024 Aug 02;12(15): [PMID: 39120239]
  6. Nurs Child Young People. 2023 Sep 7;35(5):14-21 [PMID: 36752164]
  7. Curr Opin Virol. 2023 Aug;61:101337 [PMID: 37544710]
  8. Vaccine. 2023 Jul 19;41(32):4636-4638 [PMID: 37328353]
  9. Cardiol Young. 2024 Apr 26;:1-8 [PMID: 38664919]
  10. J Pediatric Infect Dis Soc. 2023 Dec 16;12(12):638-641 [PMID: 37944043]
  11. Expert Rev Vaccines. 2022 Oct;21(10):1523-1531 [PMID: 35929971]
  12. Vaccine. 2019 Jan 21;37(4):565-570 [PMID: 30598385]
  13. Am J Perinatol. 2001 Sep;18(6):345-52 [PMID: 11607852]
  14. Vaccine. 2023 Dec 7;41(50):7503-7514 [PMID: 37977941]
  15. Vaccine. 2022 Jul 29;40(31):4121-4127 [PMID: 35667912]
  16. N Engl J Med. 2023 Dec 14;389(24):2233-2244 [PMID: 38091530]
  17. Hum Vaccin Immunother. 2019;15(2):283-286 [PMID: 30252609]
  18. PLoS One. 2017 Jan 30;12(1):e0170877 [PMID: 28135305]
  19. Hum Vaccin Immunother. 2024 Dec 31;20(1):2358566 [PMID: 38847198]
  20. Immun Inflamm Dis. 2024 Apr;12(4):e1257 [PMID: 38661110]
  21. Front Cell Infect Microbiol. 2022 Feb 25;12:858629 [PMID: 35281439]
  22. J Clin Med. 2023 May 15;12(10): [PMID: 37240575]
  23. Infect Dis Rep. 2024 Mar 29;16(2):317-355 [PMID: 38667752]
  24. Matern Child Health J. 2024 Oct;28(10):1822-1832 [PMID: 39141202]
  25. Lancet. 2022 May 28;399(10340):2047-2064 [PMID: 35598608]
  26. Clin Dev Immunol. 2013;2013:801581 [PMID: 23878586]
  27. Vaccine. 2024 Oct 3;42(23):126050 [PMID: 38902186]
  28. Vaccines (Basel). 2024 May 20;12(5): [PMID: 38793811]
  29. MMWR Morb Mortal Wkly Rep. 2024 Aug 15;73(32):696-702 [PMID: 39146277]
  30. Biologicals. 2024 Feb;85:101750 [PMID: 38360428]
  31. Front Immunol. 2022 Apr 28;13:880368 [PMID: 35572550]
  32. Infect Dis Rep. 2024 Feb 15;16(1):128-141 [PMID: 38391588]
  33. JAMA Netw Open. 2023 Feb 1;6(2):e230023 [PMID: 36800182]
  34. Vaccine. 2023 Apr 17;41(16):2707-2715 [PMID: 36941154]
  35. J Int Med Res. 2000 Sep-Oct;28(5):207-13 [PMID: 11092230]
  36. Pediatrics. 2024 Dec 1;154(6): [PMID: 39587878]
  37. NPJ Vaccines. 2024 Oct 31;9(1):210 [PMID: 39482296]
  38. Ital J Pediatr. 2024 Feb 29;50(1):35 [PMID: 38424627]
  39. Vaccine. 2019 Oct 16;37(44):6743-6749 [PMID: 31540809]
  40. PLoS One. 2018 Dec 7;13(12):e0208601 [PMID: 30532274]
  41. Health Psychol. 2025 Feb;44(2):119-128 [PMID: 39311814]
  42. Vaccines (Basel). 2023 Aug 19;11(8): [PMID: 37631954]
  43. Pediatr Pulmonol. 2010 Aug;45(8):772-81 [PMID: 20632403]
  44. Arch Pediatr. 2024 Nov;31(8):484-492 [PMID: 39261198]
  45. Influenza Other Respir Viruses. 2023 Jan;17(1):e13031 [PMID: 36369772]
  46. Pediatr Rep. 2023 Feb 20;15(1):154-174 [PMID: 36810343]
  47. Am J Perinatol. 2010 Mar;27(3):219-23 [PMID: 19784911]
  48. Curr Top Microbiol Immunol. 2013;372:3-38 [PMID: 24362682]
  49. Vaccines (Basel). 2022 Aug 18;10(8): [PMID: 36016237]
  50. Clin Infect Dis. 2024 Jun 14;78(6):1732-1744 [PMID: 38253338]
  51. Vaccine. 2022 Sep 2;40(37):5459-5463 [PMID: 35941034]
  52. Patient Prefer Adherence. 2009 Nov 03;3:195-203 [PMID: 19936162]
  53. Health Aff Sch. 2024 Jan 19;2(2):qxae003 [PMID: 38756549]
  54. MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1377-1382 [PMID: 38127675]
  55. Hum Vaccin Immunother. 2024 Dec 31;20(1):2310916 [PMID: 38369712]
  56. J Pharm Technol. 2024 Oct 19;:87551225241285324 [PMID: 39545246]
  57. Pediatrics. 2024 May 1;153(5): [PMID: 38660734]
  58. Public Health. 2025 Jan;238:3-6 [PMID: 39566218]
  59. Vaccine. 2023 Nov 30;41(49):7342-7347 [PMID: 37957038]
  60. NPJ Vaccines. 2020 Feb 14;5(1):16 [PMID: 32128257]
  61. N Engl J Med. 2023 Apr 20;388(16):1465-1477 [PMID: 37018468]
  62. Lancet. 2010 May 1;375(9725):1545-55 [PMID: 20399493]
  63. Hum Vaccin Immunother. 2024 Dec 31;20(1):2341505 [PMID: 38723786]
  64. Vaccine. 2025 Jan 12;44:126570 [PMID: 39612804]
  65. Clin Infect Dis. 2024 Jan 25;78(1):202-209 [PMID: 37698366]
  66. Psychol Sci Public Interest. 2017 Dec;18(3):149-207 [PMID: 29611455]
  67. Vaccine. 2024 Feb 6;42(4):801-811 [PMID: 38216441]
  68. J Infect Dis. 2024 Nov 15;230(5):1130-1138 [PMID: 38574192]
  69. J Pediatric Infect Dis Soc. 2024 Jul 12;13(Supplement_2):S115-S124 [PMID: 38554101]
  70. Acta Paediatr. 2019 Jul;108(7):1345-1349 [PMID: 30536910]
  71. BMC Pregnancy Childbirth. 2024 Mar 27;24(1):221 [PMID: 38539077]
  72. Pediatr Infect Dis J. 2025 Feb 1;44(2S):S158-S161 [PMID: 39951096]
  73. JNMA J Nepal Med Assoc. 2024 May 31;62(274):372-377 [PMID: 39356854]
  74. J Infect Dis. 2020 Oct 7;222(Suppl 7):S577-S583 [PMID: 30880339]
  75. Vaccines (Basel). 2024 Apr 15;12(4): [PMID: 38675800]
  76. N Engl J Med. 2005 Apr 28;352(17):1749-59 [PMID: 15858184]
  77. Acta Paediatr. 2024 Apr;113(4):786-794 [PMID: 38299226]
  78. Infection. 2024 Oct;52(5):1715-1724 [PMID: 37973718]
  79. Hum Vaccin Immunother. 2024 Dec 31;20(1):2357439 [PMID: 38857859]
  80. Health Policy Plan. 2025 Jan 11;40(1):23-30 [PMID: 38955674]
  81. EClinicalMedicine. 2024 Dec 09;79:102986 [PMID: 39726670]
  82. J Glob Health. 2015 Dec;5(2):020417 [PMID: 26682049]
  83. Clin Pediatr (Phila). 2016 Jul;55(8):724-37 [PMID: 26400767]
  84. Int J Circumpolar Health. 2020 Dec;79(1):1742564 [PMID: 32191589]
  85. Hum Vaccin Immunother. 2023 Aug;19(2):2258580 [PMID: 37807864]
  86. Vaccines (Basel). 2023 Jun 02;11(6): [PMID: 37376444]
  87. J Matern Fetal Neonatal Med. 2006 Apr;19(4):221-4 [PMID: 16854695]
  88. Vaccine. 2021 Oct 8;39(42):6283-6290 [PMID: 34538695]
  89. Vaccines (Basel). 2024 Jun 08;12(6): [PMID: 38932369]
  90. Clin Microbiol Infect. 2023 Jul;29(7):943.e1-943.e8 [PMID: 36914069]
  91. Vaccines (Basel). 2023 Nov 04;11(11): [PMID: 38006023]
  92. PLoS One. 2020 Jul 9;15(7):e0234827 [PMID: 32645112]
  93. Behav Med. 2025 Jan-Mar;51(1):1-6 [PMID: 39545462]
  94. N Engl J Med. 2023 Feb 16;388(7):595-608 [PMID: 36791160]
  95. Children (Basel). 2022 Dec 16;9(12): [PMID: 36553427]
  96. Pediatr Rep. 2022 Mar 24;14(2):147-165 [PMID: 35466200]
  97. Children (Basel). 2023 Jan 20;10(2): [PMID: 36832327]
  98. JAMA. 2003 Jan 8;289(2):179-86 [PMID: 12517228]
  99. Health Sci Rep. 2025 Jan 07;8(1):e70319 [PMID: 39777284]
  100. Vaccine. 2025 Jan 12;44:126541 [PMID: 39616950]

Word Cloud

Created with Highcharts 10.0.0RSVprevention:attitudesimmunizationavailableacceptanceknowledgevaccinationn=infantoptionsstrategiesrespiratorysyncytialvirussystematicreviewAPAarticlesfocusingpreferencesgenerallytowardsAttitudesfavorableNewdevelopmentcrucialeffectivenessObjectives:aimssummarizecurrentquantitativequalitativeevidenceregardingrelatingSixdatabasesPubMedScopusPsycArticlesPsycInfoCINAHLCompletePsychologyBehavioralSciencesCollectiontwopreprintrepositoriesmedRxivPreprintssearched23December2024PROSPERO:CRD42024602351Sixty-oneincludedelderlyadultsrisk10pregnantpeople248alsoexaminedmaternalvs2716focusedpalivizumab6adherencemonthlyadministrationEighteenassessedhealthcareprofessionalsOverallfindingsshowedlimitedawarenesspositivemoderatehighintentionsuptakeratesProtectiondiseaseperceivedseveritypromotedwhereasconcernssideeffectshinderedMaternalacceptablebecomemaydependcharacteristicsframedpresentedinsightshighlightimportanceeducationgroundeddecision-makingliteraturerecognizinglikelyreceptionpreventivemeasuresacrosstargetage-populationsKnowledgeRegardingRespiratorySyncytialVirusPrevention:SystematicReviewintentionmonoclonalantibody

Similar Articles

Cited By